ADA Scientific Sessions 2025 Abstract

A Multicenter, Randomized, Open-Label, Controlled Study on Evaluating the Efficacy and Safety of Switching from Daily DPP-4 Inhibitors to Cofrogliptin in Patients with Type 2 Diabetes Mellitus in China

By Congqing Pan, Liming Chen, Hongwei Jiang, Yusen Zhou

Trial in peopleInterventions

The paper

Congqing Pan, Liming Chen, Hongwei Jiang, Yusen Zhou

Tianjin

ADA Scientific Sessions 2025 Abstract, 13 Jun 2025

Presented at ADA Scientific Sessions 2025, poster 863-P

doi.org/10.2337/db25-863-p

Lancet4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs